A look at Genentech’s strategy for Research and Development

Today, we feature a video from BIO-Europe Spring. Mike Crowley at Genentech who works in the Research and Early Development portfolio shares some insight on his group and how they work to develop drugs from discovery through clinical proof of concept. His company is unique as they also the company has two arms with the same function – Roche also has a research and development arm. Although the two have the same overarching company, it allows for a diverse work style within the parent company and allows each branch to reach their desired products and portfolios.

In this interview, Mike shares:

• - Michael’s background and how he came to start working with this Research and Early Development Group
• - How to get the attention of this group to schedule meetings with them while at partnering events.
• - Genentech’s focus on Oncology and Inflammatory diseases and how they will differentiate their products moving forward

During the interview, he makes the statement “the abundance of therapies on the market doesn’t equate to all the needs of the patients being met.” They take the effort to really understand the disease state of the patients who aren’t responding to existing therapies.

Watch the full interview here.

Are you intersted in finding out more about our BioEurope Event Series?  The next event will take place  is BIO-Europe which will take place November 3-5 in Frankfurt, Germany.  Visit the webpage to sign up for email updates and your opportunity to register at the lowest rate.

Share this article with your social network, just click below to share now!

Share |

Pfizer and Wyeth merger changes vaccine R&D structure

With the take over of Wyeth, vaccine research and development will be spread to other areas of the Pfizer and Wyeth facilities. There will be five major facilities looking to capture the research and development for the company including: Pearl River, NY, Cambridge, MA, La Jolla, CA, Groton, CT and Sandwich in the UK. Wyeth has been key in the vaccine development industry, which was appealing to Pfizer, as it's viewed as a steady revenue stream as developments allow scientists to find more way to prevent illnesses. Read more here.

This is the global drug delivery partnerships meeting place, focusing on bringing together professionals seeking the latest strategies, industry updates, and networking opportunities to help position your company for a successful partnership/collaboration. Join us today on LinkedIn or Follow us on Twitter!

Share this article with your social network, just click below to share now!

Share |

Live from Central Labs: Day 3

Central Labs Partnering event closed today which a motivational keynote from Lou Ferrigno. Pharmaceutical executives listened as Mr. Ferrigno explain how becoming fearless and taking strategic risk in this economy will lead to true success and breed innovation. In the afternoon, Wendy R. Sanhai, PhD, Senior Scientific Advisor, Office of the Commissioner, FDA; Samir Khleif, Head, Cancer Vaccine Section Investigator, NIH; William Wheeler, MD, FAAC, Global Medical Director, Centralized Cardiac Services, MDS PHARMA SERVICE; and Patrice Hugo, Vice-President of Scientific Affairs, MDS PHARMA SERVICES provided innovated strategies for working together to develop biomarkers for safety monitoring and surrogate endpoints.

IIR would like to thank all of those who attended and invite you to comment here on the event. We are looking for ideas on where to hold next year’s meeting and welcome your feedback here.

Share this article with your social network, just click below to share now!

Share |

Live from Central Labs: Day 2

Today, was the second day of IIR’s Annual Partnering with Central Labs event. Kenneth Kaitlin, PhD, Director and Professor of Medicine, TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT, kicked off the meeting with a dynamic and engaging talk that discussed the current environment for pharmaceutical innovation, Tufts CSDD’s Annual Report on Trends in Drug Development, and new R&D strategies. The audience then heard J. Rick Turner, PhD, President and Chief Scientific Officer, TURNER MEDICAL COMMUNICATIONS, discuss Drug Safety Evaluation with a focus on benefit-risk assessments throughout development and therapy

which was followed by the grand opening of the Labs networking hall. The hall houses over close to 50 companies representing the nation’s leading central labs, imaging and ECG labs, in addition to numerous CROs and ancillary service providers.

This afternoon, participants broke into three tracks on Central lab Relationship Development, Standardization in Imaging Studies, and Improving & Standardizing ECG and Cardiac Safety Studies in which multiple panel sessions allowed for open discussions and debate. Participants were engaged, asking lots of questions to get the answers to their most pressing challenges in managing outsourcing lab partnerships.

The day closed with a reception hosted by the conference sponsor Esoterix. The Central Labs participants attended and visited with their outsourcing partners and looked for new services with some of the event new exhibitors including MNX Global LifeScience Logistics and diaDexus.

Share this article with your social network, just click below to share now!

Share |

Live from Central Labs: Day 1

IIR’s 7th Annual Central Labs Partnering with Central Labs, ECG, & Imaging Labs opened today at the Red Rock Resort and Spa in a Las Vegas, NV. In the wake of the news that will likely be the biggest deal of 2010, Pfizer’s acquisition of Wyeth, experts convened to discuss and share best practices partnering strategic Small Pharmaceutical Companies and uncover the latest strategies in biomarkers, personalized medicine, diagnostics and assay development.

Over 250 outsourcing executives from large and small biopharmaceutical companies including Amgen, Pfizer, Novartis and Celgene convened with the world’s largest central labs including Icon, Covance, and MDS Pharma Services.

Monday’s attendees heard about innovative ways to better manage outsourcing partnerships and improve and streamline clinical trials operations. In addition, they received a deeper understanding of the how new developments in biomarkers, personalized medicine, diagnostics and assay development will change the face of drug development in the immediate future.

The day closed with a wonderful reception hosted by Huntingdon Life Sciences. Dr. Douglas King, Director of Business Development for DCL Medical Laboratories said to one of the conference organizers “This is such a great event. You can look around the room and see deals being made!” Despite concerns about the economy and continued mergers the buzz was great as participants recognize that as large pharma continues to downsize their workforces outsourcing will continue to be a go to strategy for the long haul. Finally, after the close of the reception attendees left for the evening to meet one on one with their partners and take advantage of the beautiful casino at the Red Rock.

Share this article with your social network, just click below to share now!

Share |